OMERS ADMINISTRATION Corp Sells 735 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• OMERS ADMINISTRATION Corp has reduced its stake in Alnylam Pharmaceuticals by 14%, holding 4,517 shares valued at approximately $1.22 million as of the end of the most recent quarter.
• Several equities analysts have upgraded Alnylam Pharmaceuticals, with 22 analysts rating the stock as a Buy and a target price averaging $405.33.
• Alnylam Pharmaceuticals reported earnings of $0.32 per share, significantly surpassing the consensus estimate of ($0.54), while revenues reached $773.69 million for the quarter.

OMERS ADMINISTRATION Corp cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 14.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,517 shares of the biopharmaceutical company's stock after selling 735 shares during the period. OMERS ADMINISTRATION Corp's holdings in Alnylam Pharmaceuticals were worth $1,220,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Ieq Capital LLC raised its holdings in shares of Alnylam Pharmaceuticals by 13.4% during the first quarter. Ieq Capital LLC now owns 44,014 shares of the biopharmaceutical company's stock worth $11,885,000 after purchasing an additional 5,208 shares during the period. Caisse DE Depot ET Placement DU Quebec boosted its position in shares of Alnylam Pharmaceuticals by 137.2% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 23,763 shares of the biopharmaceutical company's stock valued at $6,416,000 after purchasing an additional 13,745 shares in the last quarter. Comerica Bank boosted its position in shares of Alnylam Pharmaceuticals by 23.3% during the 1st quarter. Comerica Bank now owns 17,253 shares of the biopharmaceutical company's stock valued at $4,659,000 after purchasing an additional 3,262 shares in the last quarter. Jump Financial LLC boosted its position in shares of Alnylam Pharmaceuticals by 3.8% during the 1st quarter. Jump Financial LLC now owns 15,717 shares of the biopharmaceutical company's stock valued at $4,244,000 after purchasing an additional 572 shares in the last quarter. Finally, SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $27,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock traded up $6.11 during trading on Thursday, reaching $453.54. The company's stock had a trading volume of 714,264 shares, compared to its average volume of 960,051. The stock has a 50-day moving average price of $382.18 and a two-hundred day moving average price of $306.55. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $469.81. The stock has a market capitalization of $59.45 billion, a P/E ratio of -183.62 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. During the same period in the previous year, the business posted ($0.13) earnings per share. The firm's revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the subject of several recent analyst reports. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a report on Friday, August 1st. BMO Capital Markets raised their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research report on Tuesday, June 24th. Chardan Capital lifted their price target on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Jefferies Financial Group lifted their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research report on Monday, July 7th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $412.79.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,455 shares of the business's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total transaction of $666,986.55. Following the completion of the sale, the executive vice president directly owned 20,221 shares of the company's stock, valued at approximately $9,269,508.61. The trade was a 6.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $1,030,735.98. Following the completion of the sale, the executive vice president directly owned 50,121 shares of the company's stock, valued at approximately $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 57,594 shares of company stock worth $25,551,456. Corporate insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.